Prescribing a healthy dose of skepticism to reveal a wealth of possibility: Corporate social responsibility and the challenge to improve access to medicine in low-income countries

Journal of Public and International Affairs

Volumn 23, Issue , 2012, Pages 153-175

  Wilson, Tim ^a  

^a Howard Hughes Medical Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84870386283     PISSN: 1070521X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Allen, Tim and Melissa Parker. 2011. The 'Other Diseases' of the Millenium Development Goals: Rhetoric and Reality of Free Drug Distribution to Cure the Poor's Parasites. Third World Quarterly 32(1): 91-117.
2. Allen, Tim, Melissa Parker, and Julie Hastings. 2008. Resisting Control of Neglected Tropical Diseases: Dilemmas in the Mass Treatment of Schistosomiasis and Soil-Transmitted Helminths in North-West Uganda. Journal of Biosocial Science 40(2): 161-181.
3. Altman, Daniel. 2011. Innovating for Every Woman, Every Child. World Health Organization's Innovation Working Group.
4. Baker, Brook and Eva Ombaka. 2008. The Danger of In-Kind Drug Donations to the Global Fund. Viewpoint-HealthGap Global Access Project. http://www.healthgap.org/documents/bakerandombaka.lancet-drugdonations.print.pdf (accessed December 10, 2011).
5. Bansal, Sarika. 2011. Top Five Ways Big Pharma can Address Neglected Diseases. Forbes, November 22. http://www.forbes.com/sites/sarikabansal/2011/ll/22/top-five-ways-big-pharma-neglected-diseases/ (accessed December 9, 2011).
6. Bluestone, Ken, Annie Heaton, and Christopher Lewis. 2002. Beyond Philanthropy: The Pharmaceutical Industry, Corporate Social Responsibility and the Developing World. Oxford and London: Oxfam, Save the Children Fund, and VSO.
7. Bollier, David, Stephanie Weiss, and Kirk Hanson. 1991. Merck & Co Inc.: Addressing Third World Needs (A, B, C, D). The Business Enterprise Trust, http://www.caseplace.org/d.asp?d=93 (accessed December 6, 2011).
8. Burns, Melinda. 2010. Lifesaving Drug Praziquantel Too Expensive for Africa. Miller-McCune-Health, October 3.
9. Cameron, Alexandra, Margaret Ewen, Dennis Ross-Degnan, Douglas Ball, and Richard Laing. 2009. Medicine Prices, Availability, and Affordability in 36 Developing and Middle-Income Countries: A Secondary Analysis. The Lancet 373(9659): 240-49.
10. Capell, Kerry. 2004. Vaccinating the World's Poor-Glaxo is Betting it can Combat Third World Scourges-and Still Make Money. Business Week Online, April 26. http://www.businessweek.com/magazine/content/04_17/b3880098.htm (accesed May 22, 2012).
11. CNN Money. 2011. Fortune 500: Pharmaceutical Industry Rankings 2011. May 23. http://moneycnn.com/magazines/fortune/fortune500/2011/industries/21/index.html (accessed December 9, 2011).
12. Colalife. 2011. About Us-Colalife. http://www.colalife.org/about/colalife-about/ (accessed December 18, 2011).
13. Drisdelle, Rosemary. 2007. Eliminating River Blindness. Microbiology Suite 101, July 4. http://rosemary-drisdelle.suitel01.com/eliminating-river-blindness-a25397 (accessed December 14, 2011).
14. The Economist. 2003. Big Trouble for Big Pharma. The Economist-Print Edition, December 4.
15. Frynas, Jedrzej George. 2005-The False Development Promise of Corporate Social Responsibility. International Affairs 81: 581-598.
16. Glassman, Amanda. 2011. The Elusive Power of mHealth. Global Health Policy-Center for Global Development. October 4. http://blogs.cgdev.org/global-health/2011/10/the-elusive-power-of-mhealth.php?utm http://blogs.cgdev.org/globalhealth/2011/10/the-elusive-power-of-mhealth.php?utm (accessed December 11,2011).
17. Glaxo Smith Kline. 2011. GSK Forms Partnership with Three Leading NGOs to Address Shortage of Frontline Healthcare Workers in Least Developed Countries (LDCs). May 24. http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-436669.htm (accessed December 11, 2011).
18. Global Alliance for Vaccines and Immunization (GAVI).2011. What We Do: GAVI. http://www.gavialliance.org/about/mission/what/(accessed December 9,2011).
19. The Global Fund. 2011a. Donors and Contributors, http://www.theglobalfund.org/en/about/donors/ (accessed December 16, 2011).
20. The Global Fund. 2011b. The Global Fund: Homepage, http://www.theglobalfund.org/en/ (accessed December 15, 2011).
21. Heal, Geoffrey. 2008. When Principles Pay. New York: Columbia University Press.
22. Hogerzeil, Hans and Zafar Mirza. 2011. The World Medicines Situation 2011. Geneva: World Health Organization.
23. IMS Institute. 2011a. IMS Institute. December 9. http://www.imshealth.com/portal/site/Imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=119717f27128b210VgnVCM100000edl52ca2RCRD&vgnextchanne I=4la67900b55a51lOVgnVCM10000071812ca2RCRD&vgnextfmt=default (accessed December 9, 2011).
24. IMS Institute. 2011b. The Global Use of Medicines: Outlook Through 2015. Parsippany, NJ: IMS Institute for Healthcare Informatics.
25. Jack, Andrew. 2007. Corners are Cut in Order to Bring Drugs to Africa. Financial Times, March 30.
26. Jenkins, Rhys. 2005 Globalization, Corporate Social Responsibility and Poverty. International Affairs 81: 525-540.
27. Krugman, Paul, Maurice Obstfeld, and Marc Melitz. 2011. International Economics-Theory and Policy: 9th Edition. Boston: Addison-Wesley.
28. Lee, Matthew and Jilian Kohler. 2010. Benchmarking and Transparency: Incentives for the Pharmaceutical Industry's Corporate Social Responsibility. Journal of Business Ethics 95: 641-648.
29. Lester, Richard, Paul Ritvo, Edward Mills, Antony Kariri, Sarah Karanja, Michael Chung, William Jack, James Habyarimana, Mohsen Sadatsafavi, Mehdi Naj afza-deh, Carlo Marra, Benson Estambale, Elizabeth Ngugi, T. Blake Ball, Lehana Thabane, Lawrence Gelmon, Joshua Kimani, Marta Ackers, and Francis Plum-mer. 2010. Effects of a Mobile Phone Short Message Service on Antiretroviral Treatment Adherence in Kenya. The Lancet 376(9755): 1838-1845
30. Little, Mark. 2010. Universal Access to HIV Services: A Promise Yet to Be Realized. BSR Insight, November 30.
31. Liverpool School of Tropical Medicine. 2011. About NTDs. http://www.cntd.org/about_ntds/index.htm (accessed December 15, 2011).
32. Médecins Sans Frontières. 2011. About Us: Médecins Sans Frontières. http://www.msfaccess.org/the-access-campaign (accessed December 9, 2011).
33. Médecins Sans Frontières and Drugs for Neglected Diseases Working Group. 2001. Fatal Imbalance-The Crisis in Research and Development for Drugs for Neglected Diseases. MSFDocuments. http://www.doctorswithoutborders.org/publications/reports/2001/fatal_imbalance_short.pdf (accessed December 10,2011).
34. Mehrpouya, Afshin. 2010. Access to Medicine Index 2010. Access to Medicine Foundation. http://www.accesstomedicineindex.org/files/general/Access_to_Medicine_Index_2010.pdf (accessed December 10, 2011).
35. Molyneux, David, Peter Hotez, and Alan Fenwick. 2005 Rapid Impact Interventions-How a Policy of Integrated Control for Africa's Neglected Tropical Diseases Could Benefit the Poor. PIOSMedicine 2(11): e336.
36. Nelson, Julie. 2011. Does Profit-Seeking Rule Out Love? Evidence (or Not) from Economics and Law. Journal of law and Policy, 2011: 69-107.
37. Newman, Melanie. 2011. Analysis: Legal Case in IndiaThreatens HIV Drug Access for Poorest. September 12. http://www.thebureauinvestigates.com/2011/09/12/analysis-legal-case-in-india-threatens-hiv-drug-access-for-poorest/ (accessed December 18,2011).
38. Novartis. 2011. Media Releases. November 17. http://www.novartis.com/news-room/mediareleases/en/2011/1564835-shtml (accessed December 9, 2011).
39. Pan American Health Organizatino (PAHO). 2008. Operating Procedures of the PAHO Revolving Fund. http://www.paho.org/English/AD/FCH/IM/RF_OperatingProcedures_e.pdf (accessed December 18, 2011).
40. Pan American Health Organizatino (PAHO). 2011. The Revolving Fund as a Cooperation Mechanism for Immuniza tion Programs in the Americas.
41. PATH. 2008. Introducing Oxytocin in the Uniject Device: An Overview for Decision Makers. http://www.path.org/publications/files/TS_oxy_uniject_overview.pdf (accessed December 9, 2011).
42. PHARMAC. 2002. Potential Pitfall Of Drug Company Free Supply. January 9. http://www.scoop.co.nz/stories/GE0201/S00004/potential-pitfiall-of-drug-company-free-supply.htm (accessed December 9, 2011).
43. Pillai, Usha. 2011. Mobilize Against Malaria-Lessons Learned From Ghana. Malaria-Pfizer'sInvestments in Health, http://www.pfizer.com/files/responsibil-ity/global_health/mam_lessons_from_ghana_report.pdf (accessed December 13,2011).
44. Silicon India News. 2007. Astra Zeneca Opens PR&D Unit in Bangalore. March 21. http://www.siliconindia.com/shownews/Astra_Zeneca_opens_PRD_unit_in_Bangalore-nid-35373-cid-3.html (accessed December 9, 2011).
45. Standard Chartered. 2009. Community Investment-Living with HIV. http://www.standardchartered.com/sustainability/community-investment/living-with-hiv/en/index.html (accessed December 14, 2011).
46. Strom, Stephanie and Matt Fleischer-Black. 2003. Drug Maker's Vow to Donate Cancer Medicine Falls Short. The New York Times, May 5-
47. Taylor, Humphrey. 2011. The Harris Poll Interactive. September 21. http://www.har-risinteractive.com/NewsRoom/HarrisPolls/tabid/447/mid/1508/articleId/867/ctl/ReadCustom%20Default/Default.aspx (accessed December 16, 2011).
48. UNAIDS. 2011. Getting to Zero-2011-2015 Strategy, http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2010/jc2034_un-aids_strategy_en.pdf (accessed December 9, 2011).
49. United Nations Development Programme (UNDP). 2011. Human Development Report-Sustainability and Equity: A Better Future For All. New York: Palgrave Macmillan.
50. United Nations Children's Fund (UNICEF) and the World Health Organization (WHO). 2010. Sources and Prices of Selected Medicines for Children. NewYork: UNICEF and WHO.
51. William J. Clinton Foundation. 2011. Treating HIV/AIDS and Malaria, http://www.clintonfoundation.org/what-we-do/clinton-health-access-initiative (accessed December 14, 2011).
52. Woelfle, Michael, Piero Olliaro, and Matthew Todd. 2011. Open Science is a Research Accelerator. Nature Chemsitry 3: 745-748.
53. World Bank. 2011a. Country and Lending Groups, http://data.worldbank.org/about/countryclassifications/country-and-lending-groups#Low_income (accessed December 15, 2011).
54. World Bank. 2011b. Data, http://data.worldbank.org/ (accessed December 14,2011).
55. World Health Organization (WHO). 2002. River Blindness Campaign Ends: West Africans Return to Fertile Farmlands. December 4. http://www.who.int/mediacentre/news/releases/pr93/en/ (accessed December 14, 2011).
56. World Bank. 2009. Towards Universal Access-Scaling Up Priority HIV/AIDS Inte 2009. Towards Universal Access-Scaling Up Priority HIV/AIDS Inter ventions in the Health Sector-Progress Report 2009. Malta: WHO.
57. World Bank. 2010. Schistosomiasis. http://www.who.int/mediacentre/factsheets/fs115/en/index.html (accessed December 16, 2011).
58. World Bank. 2011a. Priority Eye Diseases-Onchocerciasis (River Blindness), http://www.who.int/blindness/causes/priority/en/index3.html (accessed December 14,2011).
59. World Bank. 2011b. Trachoma-Water-Related Diseases, http://www.who.int/water_sanitation_health/diseases/trachoma/en/index.html (accessed December 15,2011).
60. World Bank. 2011. Reported Malaria Cases. WHO Global Health Atlas,December 19.